FDA classifies nerve stimulator for restless legs syndrome as a lower-risk device

The Food and Drug Administration has officially classified the external lower extremity nerve stimulator used to treat Restless Legs Syndrome into Class II. This classification means the agency has determined that standard safety rules, combined with specific extra controls, are enough to ensure the devices work safely and effectively.

Why it matters: This change reduces the regulatory burden for manufacturers, potentially speeding up access to new treatments for patients with Restless Legs Syndrome. It clarifies the legal pathway for companies making these nerve stimulators and sets a precedent that could make it easier to bring similar devices to market in the future without starting from scratch each time.

Who it affects

• Manufacturers of medical devices, specifically those producing external lower extremity nerve stimulators for Restless Legs Syndrome.

---

This summary is based on a final order published by the Food and Drug Administration in the Federal Register; readers should consult the original document for full regulatory details before relying on it for compliance purposes.

Agency: Health and Human Services Department, Food and Drug Administration
Source: Federal Register — read the official document